FY/Q4 2018 Investor Conference Call

Wednesday, February 27, 2019
Start at approx. 2:00 p.m. CET (1:00 p.m. UTC)


Investor News February 27, 2020

Fiscal 2018:

Bayer increases sales and earnings - leader in agriculture after acquisition

Group sales advance 4.5 percent (Fx & portfolio adj.) to 39.586 billion euros / EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros / Pharmaceuticals posts higher sales (Fx & portfolio adj.) and slightly lower earnings / Consumer Health: sales level with prior year (Fx & portfolio adj.), earnings decline / Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start / Positive safety profile of glyphosate unchanged - Bayer vigorously defending itself against lawsuits/ Net income at 1.695 billion euros, impacted by one-time effects / Core earnings per share at 5.94 euros, above expectations / Net financial debt at 35.679 billion euros, significantly better than expected / Bayer confirms 2019 Group outlook and 2022 targets MORE

 


baumann

Werner Baumann
CEO of Bayer AG

Audio recording of the presentations and discussion

 

Audio file

You can also play the audio recording on your mobile device.

 

nickl

Wolfgang Nickl
CFO of Bayer AG

Presentation charts

Annual Report 2018

Q4 2018 Analyst and Investor Briefing

Transcript

FY/Q4 2018 All in One Package for Investors and Analysts

Restatement of Q2 and Q3 2018 due to PPA of Monsanto Acquisition